BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) CMO William P. Sheridan sold 64,310 shares of the company’s stock in a transaction on Monday, November 13th. The shares were sold at an average price of $4.72, for a total value of $303,543.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) traded down $0.11 during trading hours on Friday, reaching $4.52. The company’s stock had a trading volume of 2,299,940 shares, compared to its average volume of 1,568,436. BioCryst Pharmaceuticals, Inc. has a 52-week low of $3.95 and a 52-week high of $9.25. The company has a current ratio of 2.53, a quick ratio of 2.53 and a debt-to-equity ratio of 0.21.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.18) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.18). BioCryst Pharmaceuticals had a negative return on equity of 123.16% and a negative net margin of 167.58%. The firm had revenue of $8.76 million for the quarter, compared to analysts’ expectations of $5.05 million. During the same period in the prior year, the business posted ($0.16) earnings per share. The business’s revenue was up 12.9% compared to the same quarter last year. research analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.72 EPS for the current fiscal year.
BCRX has been the subject of a number of recent research reports. ValuEngine lowered BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday, September 3rd. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of BioCryst Pharmaceuticals in a research note on Wednesday, September 6th. J P Morgan Chase & Co upped their target price on BioCryst Pharmaceuticals from $4.93 to $9.00 and gave the company a “neutral” rating in a research note on Wednesday, September 6th. Zacks Investment Research lowered BioCryst Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, August 10th. Finally, BidaskClub upgraded BioCryst Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Tuesday, August 1st. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and seven have issued a buy rating to the stock. BioCryst Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $9.13.
Several hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. grew its holdings in shares of BioCryst Pharmaceuticals by 19.9% during the second quarter. Vanguard Group Inc. now owns 6,007,815 shares of the biotechnology company’s stock worth $33,404,000 after purchasing an additional 996,052 shares during the last quarter. RA Capital Management LLC grew its holdings in shares of BioCryst Pharmaceuticals by 47.9% during the second quarter. RA Capital Management LLC now owns 5,162,242 shares of the biotechnology company’s stock worth $28,702,000 after purchasing an additional 1,672,447 shares during the last quarter. Janus Henderson Group PLC bought a new stake in shares of BioCryst Pharmaceuticals during the third quarter worth $23,762,000. State Street Corp grew its holdings in shares of BioCryst Pharmaceuticals by 72.0% during the second quarter. State Street Corp now owns 3,909,013 shares of the biotechnology company’s stock worth $21,736,000 after purchasing an additional 1,636,909 shares during the last quarter. Finally, VHCP Management II LLC grew its holdings in shares of BioCryst Pharmaceuticals by 27.9% during the third quarter. VHCP Management II LLC now owns 3,165,457 shares of the biotechnology company’s stock worth $16,587,000 after purchasing an additional 690,290 shares during the last quarter. Institutional investors own 71.30% of the company’s stock.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.
What are top analysts saying about BioCryst Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for BioCryst Pharmaceuticals Inc. and related companies.